Vigil Neuroscience

Vigil Neuroscience

生物技术研究

Watertown,MA 8,647 位关注者

Harnessing the power of microglia to transform treatments for neurodegenerative diseases

关于我们

Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in our efforts to develop precision-based therapies to improve the lives of patients and their families. VGL101, our lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. We are also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) in genetically defined subpopulations.

网站
https://www.vigilneuro.com
所属行业
生物技术研究
规模
51-200 人
总部
Watertown,MA
类型
上市公司
创立
2020
领域
neuroscience和microglia

地点

  • 主要

    100 Forge Rd

    Suite 700

    US,MA,Watertown,02472

    获取路线

Vigil Neuroscience员工

动态

相似主页

查看职位

融资

Vigil Neuroscience 共 3 轮

上一轮

上市后股权

US$40,000,000.00

投资者

Sanofi
Crunchbase 上查看更多信息